NCT03355573

A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis

A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 255 (actual)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a study to assess the long term safety and tolerability of bimekizumab in subjects with ankylosing spondylitis

Conditions

• Ankylosing Spondylitis

Interventions

Type	Name	Description
DRUG	Bimekizumab	Bimekizumab at a prespecified dose.

Timeline

• Start date: 2017-11-28
• Primary completion: 2022-10-19
• Completion: 2022-10-19
• First posted: 2017-11-28
• Last updated: 2024-11-21
• Results posted: 2024-11-13

Locations

50 sites across 10 countries: United States, Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Russia, Spain, Ukraine

Regulatory

• FDA-regulated drug study